Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual ConferenceGlobeNewsWire • 07/15/26
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor SymposiumGlobeNewsWire • 07/06/26
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1GlobeNewsWire • 06/13/26
Belite Bio, Inc (BLTE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/08/26
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewsWire • 06/02/26
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 05/20/26
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in SwitzerlandGlobeNewsWire • 05/18/26
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)GlobeNewsWire • 05/15/26
Belite Bio, Inc (BLTE) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/14/26
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial ResultsGlobeNewsWire • 05/13/26
Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor Conference TranscriptSeeking Alpha • 04/28/26
Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28thGlobeNewsWire • 04/22/26
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company WebsiteGlobeNewsWire • 03/31/26
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 03/02/26
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary SharesGlobeNewsWire • 12/02/25
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary SharesGlobeNewsWire • 12/01/25
Belite Bio, Inc (BLTE) Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease TranscriptSeeking Alpha • 12/01/25
New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt DiseaseGlobeNewsWire • 12/01/25